FeesSafety
Pluang+

Seanergy Maritime sets Q2 2026 earnings release and webcast for July 30, 2026

Company Fundamentals
27 Jul 2026
GlobeNewsWire
View Source
Neutral
Seanergy Maritime sets Q2 2026 earnings release and webcast for July 30, 2026

Seanergy Maritime Holdings Corp. announced it will release its financial results for the second quarter and first half of 2026 on July 30, 2026, before the New York market opens. The company will host a conference call and webcast at 10:00 a.m. Eastern Time to discuss the results. Seanergy operates a fleet of Capesize vessels and is expanding its fleet size. Investors can access the webcast and presentation via the company’s website. This update is important for stakeholders tracking the company's financial health and growth plans.

More News

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...

Others
Bullish
51 minutes ago
XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...

Market News
Bullish
1 hour ago
XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...

Market News
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
2 hours ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App